Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 5, No 1 (2020)
Review article
Published online: 2020-03-31
View PDF Download PDF file
Get Citation

Creative scientific dispute — different points of view on the protocol and execution of the ISAR-REACT 5 trial

Jacek Kubica1, Miłosz Jaguszewski2, Małgorzata Ostrowska1, Piotr Adamski1
DOI: 10.5603/MRJ.a2020.0008
·
Medical Research Journal 2020;5(1):41-45.
Affiliations
  1. Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland
  2. 1st. Department of Cardiology, Medical University of Gdansk, ul. Dębinki 7, 80-211 Gdańsk, Poland

open access

Vol 5, No 1 (2020)
REVIEW ARTICLES
Published online: 2020-03-31

Abstract

Discordant interpretations of the results of clinical trials often drive scientific disputes. Our position concerning the protocol and performance of the ISAR-REACT 5 trial have been termed as false and groundless in the recently published article. We deeply disagree with this judgement and still maintain all our opinions expressed in the previous publications, without any exceptions. As demonstrated in multiple studies, prasugrel has excellent effectiveness and predictability. In our previous publications, it was not the drug itself that we put under criticism, but rather the quality of the trial assessing the drug. As a consequence of this critical approach, we stated that taking into account the serious limitations of the ISAR-REACT 5 trial, its results should be taken with cautiousness. To summarize, we remain open to further creative scientific dispute enriching both readers and authors.

Abstract

Discordant interpretations of the results of clinical trials often drive scientific disputes. Our position concerning the protocol and performance of the ISAR-REACT 5 trial have been termed as false and groundless in the recently published article. We deeply disagree with this judgement and still maintain all our opinions expressed in the previous publications, without any exceptions. As demonstrated in multiple studies, prasugrel has excellent effectiveness and predictability. In our previous publications, it was not the drug itself that we put under criticism, but rather the quality of the trial assessing the drug. As a consequence of this critical approach, we stated that taking into account the serious limitations of the ISAR-REACT 5 trial, its results should be taken with cautiousness. To summarize, we remain open to further creative scientific dispute enriching both readers and authors.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Prasugrel, ticagrelor, antiaggregation drugs, acute coronary syndrome, clinical trials

About this article
Title

Creative scientific dispute — different points of view on the protocol and execution of the ISAR-REACT 5 trial

Journal

Medical Research Journal

Issue

Vol 5, No 1 (2020)

Article type

Review article

Pages

41-45

Published online

2020-03-31

Page views

732

Article views/downloads

717

DOI

10.5603/MRJ.a2020.0008

Bibliographic record

Medical Research Journal 2020;5(1):41-45.

Keywords

Prasugrel
ticagrelor
antiaggregation drugs
acute coronary syndrome
clinical trials

Authors

Jacek Kubica
Miłosz Jaguszewski
Małgorzata Ostrowska
Piotr Adamski

References (75)
  1. Wożakowska-Kapłon B. Nowoczesna terapia ostrych zespołów wieńcowych oparta na prasugrelu — dostępna dla polskiego pacjenta. Folia Cardiol. 2020; 15(1): 49–55.
    CrossRef
  2. Ostrowska M, Adamski P, Kubica J. ISAR-REACT 5: should this trial change clinical practice? Folia Cardiol. 2019; 14(5): 483–487.
    CrossRef
  3. Kubica J, Jaguszewski M. ISAR-REACT 5 - What have we learned? Cardiol J. 2019; 26(5): 427–428.
    CrossRefPubMed
  4. Schulz S, Angiolillo DJ, Antoniucci D, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014; 7(1): 91–100.
    CrossRefPubMed
  5. Schüpke S, Neumann FJ, Menichelli M, et al. ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16): 1524–1534.
    CrossRefPubMed
  6. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008; 371(9621): 1353–1363.
    CrossRefPubMed
  7. Koziński M, Bielis L, Wiśniewska-Szmyt J, et al. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J. 2008; 15(6): 530–536.
    PubMed
  8. Kasprzak M, Koziński M, Bielis L, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J. 2009; 16(6): 535–544.
    PubMed
  9. Witkowski A, Maciejewski P, Wasek W, et al. STEMI 2003 Registry Collaborators. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. Eur Heart J. 2009; 30(14): 1736–1743.
    CrossRefPubMed
  10. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011; 97(2): 98–105.
    CrossRefPubMed
  11. Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM. 2011; 104(7): 561–569.
    CrossRefPubMed
  12. Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets. 2011; 22(8): 579–587.
    CrossRefPubMed
  13. Kubica A, Kozinski M, Navarese EP, et al. Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. Curr Med Res Opin. 2011; 27(11): 2133–2144.
    CrossRefPubMed
  14. Navarese EP, Kozinski M, Obonska K, et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Platelets. 2012; 23(4): 274–281.
    CrossRefPubMed
  15. Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012; 10(4): 529–542.
    CrossRefPubMed
  16. Kubica J, Adamski P, Ostrowska M, et al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res. 2012; 130(1): 65–69.
    CrossRefPubMed
  17. Koziński M, Grześk G, Kubica J. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction]. Kardiol Pol. 2012; 70(2): 206–212.
    PubMed
  18. Kubica J, Koziński M, Navarese EP, et al. Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. Cardiol J. 2012; 19(3): 230–242.
    CrossRefPubMed
  19. Koziński M, Kubica J. [High platelet reactivity during reperfusion - a new risk factor of no reflow?]. Kardiol Pol. 2012; 70(7): 685.
    PubMed
  20. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute coronary syndromes. QJM. 2013; 106(2): 105–115.
    CrossRefPubMed
  21. Tantry US, Jeong YH, Navarese EP, et al. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther. 2013; 11(4): 447–462.
    CrossRefPubMed
  22. Grześk G, Kozinski M, Tantry US, et al. High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. Biomed Res Int. 2013; 2013: 928271.
    CrossRefPubMed
  23. Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014; 30(5): 813–828.
    CrossRefPubMed
  24. Ostrowska M, Adamski P, Koziński M, et al. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. Cardiol J. 2014; 21(5): 458–464.
    CrossRefPubMed
  25. Koziński M, Obońska K, Stankowska K, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J. 2014; 21(5): 547–556.
    CrossRefPubMed
  26. Adamski P, Koziński M, Ostrowska M, et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. 2014; 112(2): 224–242.
    CrossRefPubMed
  27. Siller-Matula JM, Lang IM, Neunteufl T, et al. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One. 2014; 9(7): e102701.
    CrossRefPubMed
  28. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
    CrossRefPubMed
  29. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2015; 16: 198.
    CrossRefPubMed
  30. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
    CrossRefPubMed
  31. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
    CrossRefPubMed
  32. Stolarek W, Kasprzak M, Obońska K, et al. Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. Pharmacol Rep. 2015; 67(5): 952–958.
    CrossRefPubMed
  33. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016; 46(1): 7–14.
    CrossRefPubMed
  34. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016; 37(3): 245–252.
    CrossRefPubMed
  35. Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015; 11(4): 259–280.
    CrossRefPubMed
  36. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
    CrossRefPubMed
  37. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208.
    CrossRefPubMed
  38. Gurbel PA, Myat A, Kubica J, et al. State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis. 2016; 5: 2048004016652514.
    CrossRefPubMed
  39. Siller-Matula JM, Specht S, Kubica J, et al. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol. 2016; 82(5): 1343–1350.
    CrossRefPubMed
  40. Koziński M, Ostrowska M, Adamski P, et al. Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. Thromb Haemost. 2016; 116(6): 1140–1149.
    CrossRefPubMed
  41. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.
    CrossRefPubMed
  42. Myat A, Tantry US, Kubica J, et al. Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Rev Cardiovasc Ther. 2016; 14(12): 1361–1370.
    CrossRefPubMed
  43. Niezgoda P, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017; 117(4): 718–726.
    CrossRefPubMed
  44. Kubica J, Adamski P, Paciorek P, et al. Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. Kardiol Pol. 2017; 75(4): 399–408.
    CrossRefPubMed
  45. Adamski P, Ostrowska M, Sikora J, et al. Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open. 2017; 7(4): e013218.
    CrossRefPubMed
  46. Schoergenhofer C, Hobl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017; 117(8): 1582–1587.
    CrossRefPubMed
  47. Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013.
    CrossRefPubMed
  48. Wolff G, Navarese EP, Brockmeyer M, et al. Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2018; 258: 59–67.
    CrossRefPubMed
  49. Kubica J, Adamski P, Buszko K, et al. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 152–157.
    CrossRefPubMed
  50. Bartko J, Schoergenhofer C, Schwameis M, et al. Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. J Pharmacol Exp Ther. 2018; 365(2): 430–436.
    CrossRefPubMed
  51. Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint. Cardiol J. 2018; 25(3): 291–300.
    CrossRefPubMed
  52. Navarese EP, Wernly B, Lichtenauer M, et al. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. Int J Cardiol. 2018; 269: 292–297.
    CrossRefPubMed
  53. Adamski P, Buszko K, Sikora J, et al. Metabolism of ticagrelor in patients with acute coronary syndromes. Sci Rep. 2018; 8(1): 11746.
    CrossRefPubMed
  54. Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018; 19(12): 1389–1398.
    CrossRefPubMed
  55. Sikora J, Niezgoda P, Barańska M, et al. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. Thromb Haemost. 2018; 118(12): 2126–2133.
    CrossRefPubMed
  56. Kubica J, Adamski P, Buszko K, et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 139–148.
    CrossRefPubMed
  57. Umińska JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2019 [Epub ahead of print].
    CrossRefPubMed
  58. Boinska J, Koziński M, Kasprzak M, et al. Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction. Platelets. 2019 [Epub ahead of print]: 1–7.
    CrossRefPubMed
  59. Adamski P, Buszko K, Sikora J, et al. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Sci Rep. 2019; 9(1): 3924.
    CrossRefPubMed
  60. Ostrowska M, Kubica J, Adamski P, et al. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med. 2019; 6: 176.
    CrossRefPubMed
  61. Gue YX, Spinthakis N, Farag M, et al. Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther. 2020 [Epub ahead of print].
    CrossRefPubMed
  62. Adamski P, Adamska U, Ostrowska M, et al. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018; 19(13): 1415–1425.
    CrossRefPubMed
  63. Barańska M, Niezgoda P, Kubica J. The influence of naloxone on pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina pectoris receiving concomitant treatment with morphine — a protocol of a randomized trial. Med Res J. 2018; 3(4): 227–231.
    CrossRef
  64. Kołodziejczak M, Navarese E, Kubica J. Rationale and design of PREvalence of DyspneA in patients treated with TicagrelOR (PREDATOR) program. Med Res J. 2018; 3(4): 215–220.
    CrossRef
  65. Umińska J, Koziński M, Pstrągowski K, et al. Platelet reactivity during mild therapeutic hypothermia in patients with acute myocardial infarction treated with ticagrelor: study protocol of a single-centre study. Med Res J. 2017; 1(4): 115–119.
    CrossRef
  66. Niezgoda P, Sikora J, Barańska M, et al. Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study. Med Res J. 2016; 1(1): 10–14.
    CrossRef
  67. Kubica A, Kasprzak M, Obońska K, et al. Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction. Med Res J. 2016; 3(4): 154–159.
    CrossRef
  68. Adamski P, Ostrowska M, Sroka W, et al. Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo- -controlled IMPRESSION trial. Med Res J. 2015; 3(3): 100–106.
    CrossRef
  69. Kasprzak M, Molska M, Obońska K, et al. Variability of prasugrel antiplatelet effect in patients with acute coronary syndrome. Med Res J. 2015; 3(3): 117–124.
    CrossRef
  70. Laskowska E, Ostrowska M, Koziński M, et al. The influence of genetic polymorphisms of CYP2C19 and ABCB1 on ADP-induced platelet aggregation in clopidogrel-treated patients: A comparison between the index hospitalization for myocardial infarction and the 3-month follow-up visit. Folia Medica Copernicana. 2015; 3(2): 62–71.
  71. Kubica J. The optimal antiplatelet treatment in an emergency setting. Folia Medica Copernicana. 2014; 2(3): 73–76.
  72. Kubica A, Obońska K, Kasprzak M, et al. The impact of metabolic syndrome on the antiplatelet effect of clopidogrel and aspirin in patients with acute coronary syndrome. Folia Medica Copernicana. 2014; 2(2): 66–72.
  73. Kubica A, Kasprzak M, Obońska K, et al. Impact of CYP2C19 polymorphisms on antiplatelet efficacy of clopidogrel in patients after myocardial infarction. Folia Medica Copernicana. 2013; 1(1): 12–17.
  74. Kasprzak M, Koziński M, Stankowska K, et al. Enhanced antiplatelet effect of enteric-coated acetylsalicylic acid in co-administration with pantoprazole. Folia Medica Copernicana. 2013; 1(1): 5–11.
  75. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl